SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Burrage Capital Management LLC

CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770

Reported Value
$149M
Q4 2019
Positions
29
Filings on Record
8
2020–present window
Filed
Feb 14, 2020
original filing

Summary

Burrage Capital Management LLC reported $149M in U.S.-listed holdings across 29 positions for Q4 2019.

Its largest position, Epizyme, represents 15.9% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+70.0%
share of reported value
Largest Position
+15.9%
Epizyme

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $149MQ4 ’19Q1 ’20: $102MQ1 ’20Q2 ’20: $143MQ2 ’20Q3 ’20: $127MQ3 ’20Q4 ’20: $131MQ4 ’20Q1 ’21: $123MQ1 ’21Q2 ’21: $100MQ2 ’21Q3 ’21: $0Q3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 99.0%Other: 0.9%ADR: 0.1%
  • Common Stock · 99.0% · $148M
  • Other · 0.9% · $1M
  • ADR · 0.1% · $173,000

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
Epizyme IncNEW+965.5K965.5K+$24M$24M
IVERIC bio IncNEW+1.65M1.65M+$14M$14M
ArQule IncNEW+595.0K595.0K+$12M$12M
G1 Therapeutics IncNEW+414.4K414.4K+$11M$11M
PTCTPTC Therapeutics IncNEW+195.7K195.7K+$9M$9M
KIDSMEI Pharma IncNEW+185.6K185.6K+$9M$9M
NeoGenomics IncNEW+3.13M3.13M+$8M$8M
ASNDAscendis Pharma A/SNEW+43.8K43.8K+$6M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

29 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Epizyme IncCOM15.92%$24M965.5K
2IVERIC bio IncCOM9.50%$14M1.65M
3ArQule IncCOM7.96%$12M595.0K
4G1 Therapeutics IncCOM7.34%$11M414.4K
5PTCTPTC Therapeutics Inchistory →COM6.30%$9M195.7K
6KIDSMEI Pharma Inchistory →COM5.85%$9M185.6K
7NeoGenomics IncCOM5.19%$8M3.13M
8ASNDAscendis Pharma A/Shistory →SPONSORED ADR4.08%$6M43.8K
9ANABAnaptysBio Inchistory →COM3.92%$6M360.1K
10Y-mAbs Therapeutics IncCOM3.91%$6M186.7K
11NEOOrthoPediatrics Corphistory →COM3.89%$6M198.3K
12CRNXCrinetics Pharmaceuticals Inchistory →COM3.46%$5M205.7K
13Cara Therapeutics IncCOM3.07%$5M284.2K
14Aerie Pharmaceuticals IncCOM3.04%$5M188.0K
15CTMXCytomX Therapeutics Inchistory →COM2.65%$4M476.1K
16Deciphera Pharmaceuticals IncCOM2.50%$4M59.8K
17Tricida IncCOM1.79%$3M70.7K
18AUPHAurinia Pharmaceuticals Inchistory →COM1.72%$3M126.5K
19USPHUS Physical Therapy Inchistory →COM1.65%$2M21.5K
20Apellis Pharmaceuticals IncCOM1.54%$2M75.2K
21Dicerna Pharmaceuticals IncCOM1.54%$2M104.0K
22ABIOMED IncCOM1.16%$2M10.1K
23Frequency Therapeutics IncCOM0.63%$938,00053.5K
24WVEWaVe Life Sciences LtdCOM0.57%$849,000106.0K
25Adverum Biotechnologies IncCOM0.25%$366,00031.8K
26Solid Biosciences IncCOM0.24%$358,00080.5K
27Sunesis Pharmaceuticals IncCOM0.12%$185,000548.2K
28AUTLAutolus Therapeutics PLCSPON ADS0.12%$173,00013.1K
29Aduro Biotech IncCOM0.11%$160,000135.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$01Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$100M22Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$123M27May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$131M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$127M27Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$143M26Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$102M31May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$149M29Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.